Financial Daily from THE HINDU group of publications
Thursday, Jul 04, 2002

News
Features
Stocks
Port Info
Archives

Group Sites

Corporate - Announcements
Industry & Economy - Health


Hepatitis B vaccine prices slashed

Our Bureau

MUMBAI, July 3

SERUM Institute of India Ltd (SIIL) has slashed prices of its Hepatitis B vaccine, Gene Vac-B by about 40 per cent.

The maximum retail price of 10 ml vial is now Rs 875 as againt Rs 1,400 earlier. The 0.5 ml (single dose) for paediatric use will now cost Rs 55 as against Rs 90.

Speaking to presspersons in Mumbai today, Dr Cyrus Poonawalla, Chairman, Serum Institute of India Ltd, said that the company is making a major price cut of Rs 525 in the MRP of Gene Vac-B.

According to Dr Poonawalla, with this announcement, a price war is imminent in the Hepatitis B vaccine market. "Other players in this market will now have to slash prices," Dr Poonawalla said. However, there is very little scope for others to slash it further than 40 per cent, he added.

The company first launched the vaccine in the year 2001 and has garnered sales of about Rs 5 crore. "In the next 18 to 20 months, we expect to garner about Rs 20 crore sales especially after this announcement," Dr Poonawalla said.

The price reduction will cost the company a substantial loss in margins, he said. "Being a private company, we can afford to absorb the difference in margins,'' he added. The company has plans to launch two to three vaccines in the next two years." We are currently working on a combination vaccine; DTP (Diphtheria Tetanus Pertussis) and Hepatitis B. It is expected to hit the market in a year's time," Dr Poonawalla said.

The company is also working on an NDDS (New Drug Delivery System) product, which is a nasal delivery of vaccines. Other vaccines in the pipeline include the AIDS vaccine and other combination vaccines.

In the year ended March 2002, SIIL registered sales of Rs 403 crore with exports contributing about Rs 276 crore.

Send this article to Friends by E-Mail

Stories in this Section
German pharma co plans research in India on AIDS


Ranbaxy gets US FDA nod for Lisinopril
Hepatitis B vaccine prices slashed
SEBI panel findings on buyback by month-end
ICAI renames auditing practices panel — Regulatory bodies, public to have a say henceforth
Jargons ajar
HDFC subscribes to 6.9 pc preference shares of RIL
Sasken converts Japanese arm into branch office
Sesa Goa seeks to dispose of Sirsaim unit
ACC to sell stake in Intl Ferrites in Rs 40-cr deal
Idea Cellular-BPL merger in a limbo
IOC denies imposing fresh riders on HPL
Alfa Laval India to be hub for global projects business
Singareni Collieries hopes to wipe out losses this fiscal
Sanofi-Synthelabo eyes 20% growth in topline
M.K. Sinha takes over at NCL
Alstom board reconstituted


The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | The Sportstar | Frontline | Home |

Copyright 2002, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line